SAGE Sage Therapeutics Inc.

+1.43  (+1%)
Previous Close 156.72
Open 156.59
Price To Book 9.33
Market Cap 8053909828
Shares 50,925,991
Volume 271,510
Short Ratio
Av. Daily Volume 572,297

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 3 data due 4Q 2019 or 1Q 2020.
Major Depressive Disorder (MDD)
Phase 3 data met primary endpoint - January 7, 2019.
Postpartum depression (PPD)
Phase 3 data released November 9, 2017. Primary endpoint met.
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data released September 12, 2017 - primary endpoint not met.
Phase 3 data due 2020.
Phase 2 Part A data due 1H 2019.
Bipolar depression
Phase 1 biomarker data due 1H 2019 with Huntington’s Disease Phase 1 cohort data due 2H 2019.
Huntington's disease
Phase 1 data due 2H 2019.
Essential tremor
Phase 3 data due 2020.
Major Depressive Disorder (MDD)

Latest News

  1. 5 biotech stocks that could be the next big winners
  2. 2 Biotech Takeout Targets Perfect for Biogen
  3. A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me
  4. Shares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout
  5. Is Sage Therapeutics a Good Stock to Buy Now?
  6. Fed Stops the Rate Madness: Cramer's 'Mad Money' Recap (Wednesday 3/20/19)
  7. Sage Therapeutics CEO: Getting the first postpartum depre...
  8. This Biotech Stock Grabbed A First In Depression — So What's Next?
  9. The Late Morning Rundown: March 20, 2019
  10. Sage's First-Of-Its-Kind Postpartum Depression Drug Clears FDA Hurdle: What You Need to Know
  11. General Mills posts strong quarter, concerns at FedEx, done deal for Disney
  12. FDA approves postpartum depression drug created by Sage Therapeutics
  13. Sage Stock Pops on FDA Approval for Postpartum Depression Drug
  14. Stocks Lose Ground Ahead Of Federal Reserve; FedEx, Monster Tumble
  15. This Postpartum-Depression Drug Has Unusual Potential
  16. FedEx, Federal Reserve, Google, AMD, Sage Therapeutics - 5 Things You Must Know
  17. [$$] Postpartum Depression Drug Gets FDA Approval
  18. FDA approves drug for treating postpartum depression
  19. Sage gets U.S. approval for first postpartum depression therapy
  20. Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression